Replies to post #772478 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

I may be wrong Gary but despite the fact that poly ICLC has not yet been
submitted to a trial, I believe that physicians can routinely request its use
for GBM patients because at this point there is enough evidence from small trials
and RWE (including probably the UK compassionate program) that it greatly adds to
the efficacy of DCVax-L. I will have to do some research as to the cost of
adding polyICLC to the treatment but I believe the cost is low and the difference
in efficacy substantial and I believe that it will be included from the get go to
the reimbursement total. It would be a shame to not to include poly ICLC
and wait for the results of a longwinded trial.